1. Home
  2. Programs
  3. CME/CE
MinuteCE®

CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer

Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies

ReachMD Healthcare Image
Restart
Resume
Choose a format
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
  • Overview

    Platinum-resistant ovarian cancer remains a major clinical challenge, characterized by high recurrence rates, limited durable treatment options, and poor overall survival outcomes. Cadherin-6 (CDH6)-targeted antibody-drug conjugates (ADCs) represent a novel therapeutic approach that leverages the tumor-specific expression of CDH6 to deliver potent cytotoxic agents directly to cancer cells while sparing healthy tissue. Two such agents, raludotatug deruxtecan and CUSP06, are currently under active investigation. In this activity, Drs. Joyce Liu and Kathleen Moore review the rationale for CDH6-directed ADCs in platinum-resistant ovarian cancer, the supporting clinical data from these agents, and the relevance of these findings to clinical practice. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Global Learning Collaborative (GLC) has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.

    The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.

    Faculty: 
    Joyce F. Liu, MD, MPH
    Associate Chief and Director of Clinical Research
    Division of Gynecologic Oncology, Dept. of Medical Oncology
    Dana-Farber Cancer Institute
    Boston, MA

    Advisory/Consulting/Speaker’s Fees for: AbbVie, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, Genmab, GlaxoSmithKline, Loxo@Lilly, Regeneron Therapeutics, Revolution Medicine, SystImmune, Zentalis Pharmaceuticals

    Kathleen N. Moore, MD, MS
    Co-Director, Cancer Therapeutics Program
    Stephenson Cancer Center at OU Health
    University of Oklahoma, Health Science Center 
    Oklahoma City, OK

    Honoraria: Aadi Bioscience, AbbVie Inc., AstraZeneca plc, BioNTech SE, Caris Life Sciences, Corcept Therapeutics Inc., Daiichi Sankyo Company Ltd., Duality Biologics, Eisai Co. Ltd., GlaxoSmithKline plc, ImmunoGen Inc., Iovance Biotherapeutics Inc., Janssen Pharmaceuticals (Johnson & Johnson Innovative Medicine), Loxo Oncology at Eli Lilly and Company, Merck & Co. Inc., Mersana Therapeutics Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Schrödinger Inc., Takeda Pharmaceutical Company Limited, Tubulis GmbH, Verastem Oncology (Verastem Inc.), Whitehawk Therapeutics, Zentalis Pharmaceuticals Inc., Zymeworks Inc. 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose. 
    • Wilma Guerra has no relevant relationships to disclose. 
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Identify the critical unmet therapeutic needs in the management of platinum-resistant ovarian cancer that create an opportunity for biomarker-directed treatment strategies
    • Describe the mechanism of action of CDH6-targeted antibody-drug conjugates in ovarian cancer
    • Interpret emerging clinical evidence and safety profiles from early-phase trials of CDH6-directed therapies in platinum-resistant ovarian cancer
    • Discuss the potential integration of CDH6-targeted agents into future treatment strategies for platinum-resistant ovarian cancer
  • Target Audience

    This activity has been designed to meet the educational needs of oncologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with ovarian cancers.

  • Provider(s)/Educational Partner(s)


    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by independent educational grants from Merck Sharpe & Dohme LLC & Daiichi Sankyo Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free